Cardiff Oncology Q2 Loss Narrows as R&D Costs Fall; Cash Runway Extended to Q3 2027
CRDF sits 39% above its 52-week low of $0.757.
Summary
Cardiff Oncology reported Q2 operating expenses of $9.72 million, down year-over-year on lower R&D spending as clinical trials wound down. The net loss per share was $0.14, with income from operations at -$9.62 million. SG&A rose due to severance, stock option modifications, and legal costs tied to the Nerviano license dispute. A $10 million post-quarter offering extended the cash runway into Q3 2027, easing near-term liquidity concerns. The company reiterated plans to start a Phase 3 trial for onvansertib in Q1 2027, pending financing. This follows the going concern warning and license termination disclosed in May, and the positive Phase 2 data in June. The extended runway reduces immediate dilution risk, but the existential license dispute remains unresolved.
At the time of this announcement, CRDF was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.9M. The 52-week trading range was $0.76 to $3.31. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.